| An editor has nominated this article for deletion. You are welcome to participate in the deletion discussion, which will decide whether or not to retain it.Feel free to improve the article, but do not remove this notice before the discussion is closed. For more information, see the guide to deletion. Find sources: "InDevR" – news · newspapers · books · scholar · JSTOR%5B%5BWikipedia%3AArticles+for+deletion%2FInDevR%5D%5DAFD |
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Company type | Corporation |
|---|---|
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | Boulder, Colorado |
| Key people | Dr. Kathy Rowlen, CEO and CSO |
| Products | Microarray instrumentation, pathogen detection and identification |
| Website | http://www.indevr.com/ |
InDevR is a biotechnology company in Boulder, Colorado, that develops advanced life science instrumentation and assays for analysis of viruses and other microorganisms, as well as protein detection and characterization, with product focus on virus quantification and pathogen detection and identification.
History
The company was founded in 2003 by Kathy L. Rowlen, Laura R. Kuck, and John W. Birks as an LLC. The origin of the name derived from its early stage goals of instrument development and research. The company converted to a corporation in 2005 with a shift toward product sales and customer support.
In 2005, InDevR purchased majority ownership of 2B Technologies, a leader in the field of analytical instruments for atmospheric and environmental measurements. An ISO 9001:2000-certified manufacturer, 2B Technologies has produced and sold over 2,000 ozone monitors and related instruments.
InDevR is a recipient of the government-sponsored Small Business Innovation Research program. The company received a Phase I grant in 2006 to develop a revolutionary instrument for Virus Quantification from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Based on demonstration of feasibility in Phase I, InDevR received a Phase II grant in 2008. Both of these grants led directly to the creation of several high-tech jobs that continue to date as InDevR translated the funding for research and development into the commercially available Virus Counter product line.
In 2012, InDevR spun off the Virus Counter Instrument to ViroCyt, LCC. The focus of InDevR's efforts will now be on the development and commercialization of their low-density microarray technology, which can be used to improve the analysis of viruses and other microorganisms as well as detecting and characterizing proteins.
Products
Products include ampliphox, fluchip, vaxarray, and vidia.